See more : Palm Eco-Town Development Co., Ltd (002431.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Inventiva S.A. (IVA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inventiva S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Oracle Corporation (ORCL) Income Statement Analysis – Financial Results
- Fifth Third Bancorp (FITB) Income Statement Analysis – Financial Results
- Korro Bio, Inc. (KRRO) Income Statement Analysis – Financial Results
- Krungthai Card Public Company Limited (KTC.BK) Income Statement Analysis – Financial Results
- Deutsche Wohnen SE (DTCWY) Income Statement Analysis – Financial Results
Inventiva S.A. (IVA)
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 17.48M | 12.18M | 4.19M | 372.00K | 7.00M | 3.20M | 6.52M | 9.45M | 4.87M | 3.28M | 3.06M |
Cost of Revenue | -23.00K | 995.00K | 1.02M | 846.00K | 0.00 | 967.00K | 1.24M | 1.49M | 1.40M | 1.52M | 1.68M |
Gross Profit | 17.50M | 11.18M | 3.18M | -474.00K | 7.00M | 2.23M | 5.28M | 7.96M | 3.47M | 1.76M | 1.38M |
Gross Profit Ratio | 100.13% | 91.83% | 75.75% | -127.42% | 100.00% | 69.75% | 81.05% | 84.27% | 71.18% | 53.59% | 45.11% |
Research & Development | 110.01M | 60.47M | 48.45M | 23.72M | 33.79M | 31.64M | 26.73M | 22.14M | 19.64M | 16.28M | 13.75M |
General & Administrative | 13.85M | 12.91M | 11.16M | 8.50M | 4.51M | 4.51M | 4.09M | 3.25M | 3.11M | 2.65M | 2.71M |
Selling & Marketing | 1.76M | 2.58M | 364.00K | 563.00K | 8.00K | 9.00K | 37.78K | 50.56K | 112.70K | 247.32K | 325.57K |
SG&A | 15.61M | 15.50M | 11.52M | 9.06M | 4.51M | 4.52M | 4.12M | 3.30M | 3.22M | 2.90M | 3.04M |
Other Expenses | -5.43M | -6.68M | -3.66M | -2.69M | -2.09M | 257.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 120.19M | 69.29M | 56.31M | 30.09M | 36.21M | 36.42M | 26.99M | 21.49M | 19.75M | 16.75M | 15.53M |
Cost & Expenses | 120.19M | 69.29M | 56.31M | 30.09M | 36.21M | 36.42M | 26.99M | 21.49M | 19.75M | 16.75M | 15.53M |
Interest Income | 945.00K | 390.00K | 5.48M | 226.00K | 157.00K | 120.00K | 276.62K | 230.18K | 227.63K | 273.84K | 42.65K |
Interest Expense | 5.18M | 707.00K | 2.64M | 66.00K | 3.00K | 4.00K | 5.32K | 7.55K | 6.06K | 2.94K | 630.00 |
Depreciation & Amortization | 2.60M | 1.68M | 927.00K | 1.01M | 1.46M | 949.00K | 1.24M | 1.49M | 1.30M | 1.23M | 1.38M |
EBITDA | -102.04M | -57.11M | -52.27M | -31.78M | -28.36M | -32.04M | -22.00M | -11.14M | -13.91M | -12.43M | -11.42M |
EBITDA Ratio | -583.86% | -468.92% | -1,111.99% | -7,988.71% | -392.90% | -969.50% | -287.82% | -104.86% | -268.39% | -349.37% | -337.41% |
Operating Income | -102.71M | -57.11M | -52.11M | -29.72M | -30.31M | -33.25M | -20.92M | -13.02M | -15.51M | -13.47M | -12.47M |
Operating Income Ratio | -587.68% | -468.92% | -1,242.58% | -7,988.71% | -433.15% | -1,040.13% | -320.76% | -137.83% | -318.17% | -410.22% | -406.81% |
Total Other Income/Expenses | -7.11M | 2.82M | 2.84M | -3.90M | 95.00K | -111.00K | 278.00K | 460.23K | 486.14K | 745.10K | 748.35K |
Income Before Tax | -109.82M | -54.29M | -49.27M | -33.62M | -30.22M | -33.36M | -20.64M | -12.56M | -15.02M | -12.72M | -11.72M |
Income Before Tax Ratio | -628.36% | -445.80% | -1,174.82% | -9,037.63% | -431.79% | -1,043.57% | -316.49% | -132.96% | -308.20% | -387.52% | -382.39% |
Income Tax Expense | 607.00K | -20.00K | 364.00K | -2.00M | 4.00K | 253.00K | -3.41M | -5.51M | -6.20M | -5.23M | -4.58M |
Net Income | -110.43M | -54.27M | -49.64M | -31.62M | -30.22M | -33.62M | -17.23M | -7.05M | -8.82M | -7.49M | -7.13M |
Net Income Ratio | -631.84% | -445.64% | -1,183.50% | -8,500.81% | -431.85% | -1,051.49% | -264.22% | -74.59% | -181.00% | -228.26% | -232.82% |
EPS | -2.43 | -1.31 | -1.27 | -0.93 | -1.28 | -1.64 | -1.11 | -0.45 | -0.88 | -0.75 | -0.71 |
EPS Diluted | -2.43 | -1.31 | -1.27 | -0.93 | -1.28 | -1.64 | -1.11 | -0.45 | -0.88 | -0.75 | -0.71 |
Weighted Avg Shares Out | 45.35M | 41.45M | 39.17M | 33.87M | 23.52M | 20.54M | 15.52M | 15.68M | 10.03M | 10.03M | 10.03M |
Weighted Avg Shares Out (Dil) | 45.35M | 41.45M | 39.17M | 33.87M | 23.52M | 20.54M | 15.52M | 15.74M | 10.03M | 10.03M | 10.03M |
Inventiva S.A. (IVA) Q2 2022 Earnings Call Transcript
Inventiva reports its 2022 first-half financial results and provides a corporate update
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
Inventiva Reports 2022 First-Half Financial Information¹
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
Update on Inventiva's cash position and on the finance documentation with the European Investment Bank
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher
Source: https://incomestatements.info
Category: Stock Reports